Xeloda

Xeloda is a brand name of capecitabine, approved by the FDA in the following formulation(s):

XELODA (capecitabine - tablet; oral)

• 
  Manufacturer: HOFFMANN LA ROCHE
  
  Approval date: April 30, 1998
  
  Strength(s): 150MG, 500MG ^[RLD]

Has a generic version of Xeloda been approved?

No. There is currently no therapeutically equivalent version of Xeloda available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xeloda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same
  Patent 5,472,949
  Issued: December 5, 1995
  Inventor(s): Arasaki; Motohiro & Ishitsuka; Hideo & Kuruma; Isami & Miwa; Masanori & Murasaki; Chikako & Shimma; Nobuo & Umeda; Isao
  Assignee(s): Hoffmann-La Roche Inc.
  The invention relates to N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives which are useful as an agent for treating tumors, pharmaceutical compositions including the same, a method of treating tumors and a method of preparing N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives for treating tumors. Compounds of formula (I), ##STR1## wherein R.sup.1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH.sub.2)n--.sup.Y wherein Y is a cyclohexyl radical, a C.sub.1 -C.sub.4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4, and when Y is C.sub.1 -C.sub.4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R.sup.2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions, or a hydrate or solvate thereof. Compounds of formula (I) are useful in the treatment of tumors.
  
  Patent expiration dates:
  
  
  • December 14, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING TUMORS
  
  

See also...

• Xeloda Consumer Information (Drugs.com)
• Xeloda Consumer Information (Wolters Kluwer)
• Xeloda Consumer Information (Cerner Multum)
• Xeloda Advanced Consumer Information (Micromedex)
• Xeloda AHFS DI Monographs (ASHP)
• Capecitabine Consumer Information (Wolters Kluwer)
• Capecitabine Consumer Information (Cerner Multum)
• Capecitabine Advanced Consumer Information (Micromedex)
• Capecitabine AHFS DI Monographs (ASHP)